Page 133 - 2019_02-Haematologica-web

JUNB, DUSP2, SGK1 and SOCS1 mutations in THRLBCL
12. Hartmann S, Schuhmacher B, Rausch T, et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia. 2016;30(4):844–853.
13. Greiner A, Tobollik S, Buettner M, et al. Differential expression of activation- induced cytidine deaminase (AID) in nodu- lar lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol. 2005;205(5): 541–547.
14. Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood. 2006;108(3):1013–1020.
15. Khodabakhshi AH, Morin RD, Fejes AP, et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–1319.
16. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-onco- genes in B-cell diffuse large-cell lym- phomas. Nature. 2001;412(6844):341–346.
17. Mottok A, Woolcock B, Chan FC, et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lym- phoma and are associated with diminished MHC class II expression. Cell Rep. 2015;13 (7):1418–1431.
18. Mottok A, Renné C, Seifert M, et al. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood. 2009;114(20):4503–4506.
19. Morin RD, Mendez-Lago M, Mungall AJ, et
al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.
20. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lym- phoma. Proc Natl Acad Sci U S A. 2013;110(4):1398–1403.
21. Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130– 140.
22. Morin RD, Assouline S, Alcaide M, et al. Genetic landscapes of relapsed and refrac- tory diffuse large B-cell lymphomas. Clin Cancer Res. 2016;22(9):2290–2300.
23. Mareschal S, Dubois S, Viailly P-J, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2016;55(3):251– 267.
24. Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014;46(4):329–335.
25. Ljungström V, Cortese D, Young E, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood. 2016;127(8):1007–1016.
26. McGirt LY, Jia P, Baerenwald DA, et al. Whole-genome sequencing reveals onco- genic mutations in mycosis fungoides. Blood. 2015;126(4):508–519.
27. Tiacci E, Ladewig E, Schiavoni G, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018;131(22):2454–2465.
28. Storb U, Peters A, Klotz E, et al. Cis-acting sequences that affect somatic hypermuta- tion of Ig genes. Immunol Rev. 1998;162153–160.
29. Qian J, Wang Q, Dose M, et al. B cell super- enhancers and regulatory clusters recruit AID tumorigenic activity. Cell. 2014;159(7):1524–1537.
30. Wang Q, Oliveira T, Jankovic M, et al. Epigenetic targeting of activation-induced cytidine deaminase. Proc Natl Acad Sci U S A. 2014;111(52):18667–18672.
31. Mottok A, Renné C, Willenbrock K, Hansmann M-L, Bräuninger A. Somatic hypermutation of SOCS1 in lymphocyte- predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007;110(9): 3387–3390.
32. Schif B, Lennerz JK, Kohler CW, et al. SOCS1 mutation subtypes predict diver- gent outcomes in diffuse large B-cell lym- phoma (DLBCL) patients. Oncotarget. 2013;4(1):35–47.
33. Kwok RP, Lundblad JR, Chrivia JC, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature. 1994;370(6486):223–226.
34. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lym- phoma. Nature. 2011;471(7337):189–195.
haematologica | 2019; 104(2)
337